Evidence
Expert Panel Discusses Evidence Supporting Opportunities to Improve Patient Quality of Life with RT-CGM
January 18, 2023Coverage and Benefit Design Article / Publication
Pharmacy professionals and a payer representative convened an expert panel to connect available evidence and the panelists’ extensive experiences on the value of RT-CGM in improving patient quality of life. In addition, the panelists provided practical approaches to bring awareness, accessibility, and the utility of rtCGM to positively impact patient quality of life in practical applications. Managed care and payer professionals will find these real-world insights useful in characterizing the value of RT-CGM in health plan populations when making coverage determinations.
“Real-Time Continuous Glucose Monitoring: Timely Opportunities to Improve Quality of Life.” CGM Live Virtual Crossfire Series Recap. Part 2. Pharmacy Times Continuing Education. August 2021.
Learn MoreExpert Panel Highlights the Role of RT-CGM and Pharmacy Professionals in Optimizing Diabetes Management
January 18, 2023Coverage and Benefit Design Article / Publication
An expert panel composed of pharmacists and a payer professional discussed the value of RT-CGM and the role pharmacists and pharmacy technicians have in optimizing diabetes management. By making RT-CGM available to and allowing pharmacy professionals to work alongside patients, health care stakeholders can leverage the information offered by this technology to optimize diabetes management and mitigate disease impact. The panelists noted that coverage of RT-CGM through the pharmacy benefit facilitates access by allowing patients to fill their prescription directly at community pharmacies. The panelists’ insights are of use to managed care and payer professionals in determining optimal coverage policies for RT-CGM to improve outcomes among members with diabetes.
“Real-Time Continuous Glucose Monitoring: Implications for Pharmacists.” CGM Live Virtual Crossfire Series Recap. Part 1. Pharmacy Times Continuing Education. May 2021.
Learn MoreAmerican Pharmacists Association Roundtable Examines the Potential of CGM Access in the Community Pharmacy Setting
January 18, 2023Coverage and Benefit Design Article / Publication
A roundtable convened by the American Pharmacists Association reviewed the substantial body of evidence demonstrating that CGM is associated with improved glycemic control for patients with both T1D and T2D. Leading experts participating in the roundtable noted that CGM remains underutilized and that disparities in care are evident. One specific barrier to expanded utilization called out by the participants was the lack of an adequate number of providers who offer the service. Developing community pharmacy-based CGM services has been proposed as a logical solution for expanding patient access. Supporting this approach are the abundant data showing that pharmacist involvement in patient care for diabetes improves outcomes and reduces overall costs of care. Managed care and payer professionals will find this in-depth review and discussion valuable for developing their own policies for CGM coverage and access in the pharmacy setting.
American Pharmacists Association Foundation. “Expanding Access to Continuous Glucose Monitoring Technology in Community Pharmacies.” Practices Insights. May 2022.
Learn MoreSurvey By Employee Benefit News Shows Digital Health Tools From Third-Party Vendors Can Increase Utilization and Enhance Wellness Programming
January 18, 2023Population Health Article / Publication
According to a survey administered by Employee Benefit News, at least 70% of employees find high stress, depression, asthma, or diabetes disruptive enough to affect their everyday lives, including work and other responsibilities. In response, the vast majority of employers (84%) are offering digital health tools in some form that can help employees manage common chronic conditions, although only an average of 50% of employees take advantage of these benefits. Research shows employees want flexible options that offer new innovative tools to treat their chronic conditions, in addition to education to help them get started with a new program. Third-party technology vendors can assist in driving employee engagement, mitigating rising health care costs, and creating better outcomes for employees. Managed care and payer professionals will find these insights useful for developing programs that offer value to purchasers of health care.
“Optimizing Digital Health Tools to Retain and Engage Employees.” Employee Benefit News Supplement.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert Panel Discusses Evidence Supporting Opportunities to Improve Patient Quality of Life with RT-CGM
Pharmacy professionals and a payer representative convened an expert panel to connect available evidence and the panelists’ extensive experiences on the value of RT-CGM in improving patient quality of life. In addition, the panelists provided practical approaches to bring awareness, accessibility, and the utility of rtCGM to positively impact patient quality of life in practical applications. Managed care and payer professionals will find these real-world insights useful in characterizing the value of RT-CGM in health plan populations when making coverage determinations.
“Real-Time Continuous Glucose Monitoring: Timely Opportunities to Improve Quality of Life.” CGM Live Virtual Crossfire Series Recap. Part 2. Pharmacy Times Continuing Education. August 2021.
Learn MoreExpert Panel Highlights the Role of RT-CGM and Pharmacy Professionals in Optimizing Diabetes Management
January 18, 2023Coverage and Benefit Design Article / Publication
An expert panel composed of pharmacists and a payer professional discussed the value of RT-CGM and the role pharmacists and pharmacy technicians have in optimizing diabetes management. By making RT-CGM available to and allowing pharmacy professionals to work alongside patients, health care stakeholders can leverage the information offered by this technology to optimize diabetes management and mitigate disease impact. The panelists noted that coverage of RT-CGM through the pharmacy benefit facilitates access by allowing patients to fill their prescription directly at community pharmacies. The panelists’ insights are of use to managed care and payer professionals in determining optimal coverage policies for RT-CGM to improve outcomes among members with diabetes.
“Real-Time Continuous Glucose Monitoring: Implications for Pharmacists.” CGM Live Virtual Crossfire Series Recap. Part 1. Pharmacy Times Continuing Education. May 2021.
Learn MoreAmerican Pharmacists Association Roundtable Examines the Potential of CGM Access in the Community Pharmacy Setting
January 18, 2023Coverage and Benefit Design Article / Publication
A roundtable convened by the American Pharmacists Association reviewed the substantial body of evidence demonstrating that CGM is associated with improved glycemic control for patients with both T1D and T2D. Leading experts participating in the roundtable noted that CGM remains underutilized and that disparities in care are evident. One specific barrier to expanded utilization called out by the participants was the lack of an adequate number of providers who offer the service. Developing community pharmacy-based CGM services has been proposed as a logical solution for expanding patient access. Supporting this approach are the abundant data showing that pharmacist involvement in patient care for diabetes improves outcomes and reduces overall costs of care. Managed care and payer professionals will find this in-depth review and discussion valuable for developing their own policies for CGM coverage and access in the pharmacy setting.
American Pharmacists Association Foundation. “Expanding Access to Continuous Glucose Monitoring Technology in Community Pharmacies.” Practices Insights. May 2022.
Learn MoreSurvey By Employee Benefit News Shows Digital Health Tools From Third-Party Vendors Can Increase Utilization and Enhance Wellness Programming
January 18, 2023Population Health Article / Publication
According to a survey administered by Employee Benefit News, at least 70% of employees find high stress, depression, asthma, or diabetes disruptive enough to affect their everyday lives, including work and other responsibilities. In response, the vast majority of employers (84%) are offering digital health tools in some form that can help employees manage common chronic conditions, although only an average of 50% of employees take advantage of these benefits. Research shows employees want flexible options that offer new innovative tools to treat their chronic conditions, in addition to education to help them get started with a new program. Third-party technology vendors can assist in driving employee engagement, mitigating rising health care costs, and creating better outcomes for employees. Managed care and payer professionals will find these insights useful for developing programs that offer value to purchasers of health care.
“Optimizing Digital Health Tools to Retain and Engage Employees.” Employee Benefit News Supplement.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert Panel Highlights the Role of RT-CGM and Pharmacy Professionals in Optimizing Diabetes Management
An expert panel composed of pharmacists and a payer professional discussed the value of RT-CGM and the role pharmacists and pharmacy technicians have in optimizing diabetes management. By making RT-CGM available to and allowing pharmacy professionals to work alongside patients, health care stakeholders can leverage the information offered by this technology to optimize diabetes management and mitigate disease impact. The panelists noted that coverage of RT-CGM through the pharmacy benefit facilitates access by allowing patients to fill their prescription directly at community pharmacies. The panelists’ insights are of use to managed care and payer professionals in determining optimal coverage policies for RT-CGM to improve outcomes among members with diabetes.
“Real-Time Continuous Glucose Monitoring: Implications for Pharmacists.” CGM Live Virtual Crossfire Series Recap. Part 1. Pharmacy Times Continuing Education. May 2021.
Learn MoreAmerican Pharmacists Association Roundtable Examines the Potential of CGM Access in the Community Pharmacy Setting
January 18, 2023Coverage and Benefit Design Article / Publication
A roundtable convened by the American Pharmacists Association reviewed the substantial body of evidence demonstrating that CGM is associated with improved glycemic control for patients with both T1D and T2D. Leading experts participating in the roundtable noted that CGM remains underutilized and that disparities in care are evident. One specific barrier to expanded utilization called out by the participants was the lack of an adequate number of providers who offer the service. Developing community pharmacy-based CGM services has been proposed as a logical solution for expanding patient access. Supporting this approach are the abundant data showing that pharmacist involvement in patient care for diabetes improves outcomes and reduces overall costs of care. Managed care and payer professionals will find this in-depth review and discussion valuable for developing their own policies for CGM coverage and access in the pharmacy setting.
American Pharmacists Association Foundation. “Expanding Access to Continuous Glucose Monitoring Technology in Community Pharmacies.” Practices Insights. May 2022.
Learn MoreSurvey By Employee Benefit News Shows Digital Health Tools From Third-Party Vendors Can Increase Utilization and Enhance Wellness Programming
January 18, 2023Population Health Article / Publication
According to a survey administered by Employee Benefit News, at least 70% of employees find high stress, depression, asthma, or diabetes disruptive enough to affect their everyday lives, including work and other responsibilities. In response, the vast majority of employers (84%) are offering digital health tools in some form that can help employees manage common chronic conditions, although only an average of 50% of employees take advantage of these benefits. Research shows employees want flexible options that offer new innovative tools to treat their chronic conditions, in addition to education to help them get started with a new program. Third-party technology vendors can assist in driving employee engagement, mitigating rising health care costs, and creating better outcomes for employees. Managed care and payer professionals will find these insights useful for developing programs that offer value to purchasers of health care.
“Optimizing Digital Health Tools to Retain and Engage Employees.” Employee Benefit News Supplement.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
American Pharmacists Association Roundtable Examines the Potential of CGM Access in the Community Pharmacy Setting
A roundtable convened by the American Pharmacists Association reviewed the substantial body of evidence demonstrating that CGM is associated with improved glycemic control for patients with both T1D and T2D. Leading experts participating in the roundtable noted that CGM remains underutilized and that disparities in care are evident. One specific barrier to expanded utilization called out by the participants was the lack of an adequate number of providers who offer the service. Developing community pharmacy-based CGM services has been proposed as a logical solution for expanding patient access. Supporting this approach are the abundant data showing that pharmacist involvement in patient care for diabetes improves outcomes and reduces overall costs of care. Managed care and payer professionals will find this in-depth review and discussion valuable for developing their own policies for CGM coverage and access in the pharmacy setting.
American Pharmacists Association Foundation. “Expanding Access to Continuous Glucose Monitoring Technology in Community Pharmacies.” Practices Insights. May 2022.
Learn MoreSurvey By Employee Benefit News Shows Digital Health Tools From Third-Party Vendors Can Increase Utilization and Enhance Wellness Programming
January 18, 2023Population Health Article / Publication
According to a survey administered by Employee Benefit News, at least 70% of employees find high stress, depression, asthma, or diabetes disruptive enough to affect their everyday lives, including work and other responsibilities. In response, the vast majority of employers (84%) are offering digital health tools in some form that can help employees manage common chronic conditions, although only an average of 50% of employees take advantage of these benefits. Research shows employees want flexible options that offer new innovative tools to treat their chronic conditions, in addition to education to help them get started with a new program. Third-party technology vendors can assist in driving employee engagement, mitigating rising health care costs, and creating better outcomes for employees. Managed care and payer professionals will find these insights useful for developing programs that offer value to purchasers of health care.
“Optimizing Digital Health Tools to Retain and Engage Employees.” Employee Benefit News Supplement.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Survey By Employee Benefit News Shows Digital Health Tools From Third-Party Vendors Can Increase Utilization and Enhance Wellness Programming
According to a survey administered by Employee Benefit News, at least 70% of employees find high stress, depression, asthma, or diabetes disruptive enough to affect their everyday lives, including work and other responsibilities. In response, the vast majority of employers (84%) are offering digital health tools in some form that can help employees manage common chronic conditions, although only an average of 50% of employees take advantage of these benefits. Research shows employees want flexible options that offer new innovative tools to treat their chronic conditions, in addition to education to help them get started with a new program. Third-party technology vendors can assist in driving employee engagement, mitigating rising health care costs, and creating better outcomes for employees. Managed care and payer professionals will find these insights useful for developing programs that offer value to purchasers of health care.
“Optimizing Digital Health Tools to Retain and Engage Employees.” Employee Benefit News Supplement.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Visit the site to learn more about the value and use of CGM in the hospital setting.
Learn MoreJanuary 6, 2023Article / Publication / CGM Innovations
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
A comprehensive learning center for clinicians.
Learn More2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
January 6, 2023Clinical Outcomes Guidelines / Policy
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
2023 ADA Standards of Care recommend the use of RT-CGM in adults with T2D on basal insulin (level A evidence)
The 2023 Standards of Medical Care in Diabetes found Grade A evidence supporting the use of RT-CGM in adults with T1D or T2D on intensive insulin therapy and in adults with T2D on basal insulin. The American Diabetes Association (ADA) found Grade B evidence supporting the use of RT-CGM in children and adolescents with T1D on intensive insulin therapy and Grade E evidence for use of RT-CGM in children and adolescents with T2D on intensive insulin therapy. When used as an adjunct to pre- and postprandial BGM, RT-CGM can help to achieve HbA1c targets in pregnant patients with diabetes (Grade B). Based on input from experts, the ADA recommends continued access to RT-CGM through third party payers to people who have been using this technology.
American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2023. Diabetes Care. 2022; 46(Suppl 1):S111-S27.
Learn MoreJanuary 1, 2023Coverage and Benefit Design Guidelines / Policy
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Effective January 1, 2023, UnitedHealthcare (UHC) is making selected continuous glucose monitoring (CGM) devices and sensors available to Medicare Advantage members at the pharmacy point-of-sale (POS). The systems affected by this change in policy include the Dexcom G6 as well as the FreeStyle Libre 2 and 14-day versions. CGMs were previously only available to UHC Medicare Advantage members through national durable medical equipment (DME) vendors. While availability through DME vendors will remain in place, the plan sought to improve access to CGMs for members by expanding to the pharmacy POS. Managed care decision makers should take note of this change in policy as an example of how national payers are leveraging the pharmacy channel as a means of enhancing coverage and member access to beneficial diabetes technologies.
Learn MoreDecember 27, 2022Clinical Outcomes Article / PublicationLearn MoreDecember 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
December 20, 2022Coverage and Benefit Design CE Activities
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE Expired
Educational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 0.5 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE ExpiredEducational Objectives
- Describe the clinical impact of real-time continuous glucose monitoring on HbA1c, severe hypoglycemia-related events and diabetic ketoacidosis
- Assess health plan opportunities to improve HbA1c and diabetes outcomes through implementation of real-time continuous glucose monitoring interventions for patients with diabetes
- Identify key stakeholders and steps for the delivery of successful quality improvement interventions targeting patients naïve to real-time continuous glucose monitoring
Expert Faculty
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.